According to fortune business insights, The global microarrays market size was valued at USD 6.49 billion in 2024. The market is projected to grow from USD 6.85 billion in 2025 to USD 10.85 billion by 2032, exhibiting a CAGR of 6.78% during the forecast period. North America dominated the microarrays market with a market share of 43.3% in 2024.
Continue reading for more details:
https://www.fortunebusinessinsights.com/microarrays-market-114209
The Microarrays Market is segmented by offering, type, application, and end user to reflect the diverse functionalities and usage patterns of microarray technologies. By offering, the market includes products (instruments and consumables) and software & services, with products accounting for the largest share due to strong demand from research and diagnostics labs. By type, segments include DNA microarray, protein microarray, tissue microarray, and others, where DNA microarrays held dominance in 2024 because of their extensive use in gene expression and genotyping studies. By application, the market comprises drug discovery & development, diagnostics, research, and others, with research applications capturing the largest share as microarrays enable simultaneous analysis of large gene sets. By end user, the market is divided into pharmaceutical & biotechnology companies, research & academic institutes, diagnostic laboratories, and others, with research & academic institutes leading due to early adoption and strong R&D initiatives in genomics and molecular biology.
Agilent Technologies Inc. (U.S.)
Thermo Fisher Scientific Inc. (U.S.)
Bio Rad Laboratories Inc. (U.S.)
Illumina Inc. (U.S.)
Arrayit Corporation (U.S.)
CDI Labs (Puerto Rico)
Creative Biolabs (U.S.)
Creative Proteomics (U.S.)
Merck KGaA (Germany)
CD Genomics (U.S.)
The Microarrays Market was valued at approximately USD 6.49 billion in 2024 and is expected to grow from around USD 6.85 billion in 2025 to approximately USD 10.85 billion by 2032, registering a CAGR of about 6.78% during the forecast period. Growth in the Microarrays Market is propelled by rising investment in genomics and proteomics research, increasing prevalence of chronic and infectious diseases that necessitate high-throughput genetic analysis tools, and the expanding need for personalized medicine. Adoption of microarrays for drug discovery, disease diagnostics, and complex biological studies is supporting market expansion. Technological advancements in microarray platforms, coupled with broader applications in biomarker discovery and pharmacogenomics, are expected to further drive the Microarrays Market over the coming years as researchers seek more efficient and scalable molecular profiling solutions.
Despite strong prospects for growth, the Microarrays Market faces restraints that could moderate expansion. A key challenge is the increasing adoption of alternative advanced technologies such as next-generation sequencing (NGS), which offers higher sensitivity, broader genomic coverage, and the ability to detect novel genetic variants, making it a preferred choice in certain precision medicine and diagnostic applications. This shift can limit the adoption pace and revenue potential of traditional microarray platforms in some segments of genomic research. Additionally, high initial costs associated with microarray instrumentation, maintenance, and the need for specialized skilled personnel to interpret complex data may also temper market growth.
Regionally, the Microarrays Market is led by North America, which held the largest share in 2024 due to high R&D spending, established healthcare infrastructure, and strong genomics and proteomics research activities that boost demand for microarray technologies. Europe follows, with robust investments in biotechnology research and precision medicine supporting market growth. Asia Pacific is expected to be a fast-growing region, driven by expanding healthcare infrastructure, increasing research funding, and rising prevalence of chronic diseases in emerging markets such as China and India. Latin America and Middle East & Africa are expected to grow at a slower pace, with gradual improvements in healthcare infrastructure and increasing scientific research adoption contributing to incremental market expansion in these regions.